Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): A randomised open-label phase 2 study

The Lancet Oncology

Volumn 14, Issue 4, 2013, Pages 354-362

  Cortes, Jorge ^a   Feldman, Eric ^b   Yee, Karen ^c   Rizzieri, David ^d   Advani, Anjali S ^e   Charman, Anthony ^f   Spruyt, Richard ^f   Toal, Martin ^f   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f Chroma Therapeutics   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TOSEDOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE RESPIRATORY FAILURE; ADULT; AGED; ARTICLE; ASTHENIA; CELLULITIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIABETIC KETOACIDOSIS; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOKALEMIA; HYPOTENSION; INSOMNIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RESPIRATORY FAILURE; SALVAGE THERAPY; THROMBOCYTOPENIA; TOXIC HEPATITIS;

AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; GLYCINE; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MONOCYTIC, ACUTE; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION;

EID: 84875803803     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70037-8     Document Type: Article

References (12)

1. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006, 107:3481-3485.
2. Lang K, Earle CC, Foster T, Dixon D, Van GR, Menzin J Trends in the treatment of acute myeloid leukemia in the elderly. Drugs Aging 2005, 22:943-955.
3. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
4. Jousse C, Bruhat A, Harding HP, Ferrara M, Ron D, Fafournoux P Amino acid limitation regulates CHOP expression through a specific pathway independent of the unfolded protein response. FEBS Lett 1999, 448:211-216.
5. Krige D, Needham LA, Bawden LJ, et al. CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukaemic cells. Cancer Res 2008, 68:6669-6679.
6. Reid AH, Protheroe A, Attard G, et al. A first-in-man phase I and pharmacokinetic study on CHR-2797 (tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors. Clin Can Res 2009, 15:4978-4985.
7. Löwenberg B, Morgan G, Ossenkoppele G, et al. Phase I/II clinical study of tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J Clin Oncol 2010, 28:4333-4338.
8. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised Recommendations of the International Working Group for Diagnosis, Standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21:4642-4649.
9. Feldman EJ, Yee KLW, Rizzieri D, et al. Interim results of OPAL, a study of tosedostat in elderly relapsed/refractory AML. Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 6517.
10. O'Donnell MR, Appelbaum FR, Coutre SE, et al. Acute myeloid leukemia. J Natl Compr Canc Netw 2008, 6:962-992.
11. Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011, 29:3322-3327.
12. Leopold LH, Berger MS, Cheng SC, Cortes-Franco JE, Giles FJ, Estey EH Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse. Clin Adv Hematol Oncol 2003, 1:220-225.